Verona Pharma PLC

Verona Pharma PLC
Stock Exchange London Stock Exchange
EPS
GBP0.1
Market Cap
GBP61.62 M
Shares Outstanding
99.01 M
Public Float
71.55 M

Profile

Address
3 More London Riverside
London Greater London SE1 2RE
United Kingdom
Employees -
Website http://veronapharma.com
Updated 07/08/2019
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Financials

View All

Jan-Anders Karlsson
Chief Executive Officer & Executive Director
Andrew Sinclair
Non-Executive Director